Recent advancements of nanomodified electrodes - Towards point-of-care detection of cardiac biomarkers.

Bioelectrochemistry

Department of Mechanical Engineering, McMaster University, 1280 Main Street, West Hamilton, Ontario L8S 4L7, Canada; W Booth School of Engineering Practice and Technology, McMaster University, 1280 Main Street, West Hamilton, Ontario L8S 4L7, Canada. Electronic address:

Published: August 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The increasing number of deaths from cardiovascular diseases has become a substantial concern in both developed and underdeveloped countries. Rapid and on-site monitoring of this disease is urgently important to control, prevent and make awareness of public health. Recently, a lot of focus has been placed on nanomaterials and modify these nanomaterials have been explored to detect cardiac biomarkers. By implementing biosensors that are modified with novel recognition elements and more stable nanomaterials, the use of electrochemistry for point-of-care devices is more realistic every day. This review focuses on the current state of nanomaterials conjugated biorecognition elements (enzyme integrated with nanomaterials, antibody conjugated nanomaterials and aptamer conjugated nanomaterials) for electrochemical cardiovascular disease detection. Specifically, a lot of attention has been given to the trends toward more stable biosensors that have increased the potential to be used as point-of-care devices for the detection of cardiac biomarkers due to their high stability and specificity. Moreover, the recent progress on biomolecule-free electrochemical nanosensors for cardiovascular disease detection has been considered. At last, the possibility and drawbacks of some of these techniques for point-of-care cardiac device development in the future have been discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioelechem.2023.108440DOI Listing

Publication Analysis

Top Keywords

cardiac biomarkers
12
detection cardiac
8
point-of-care devices
8
conjugated nanomaterials
8
cardiovascular disease
8
disease detection
8
nanomaterials
7
advancements nanomodified
4
nanomodified electrodes
4
point-of-care
4

Similar Publications

Natural product Erianin: mitigating FOLFOX toxicity and enhancing against colorectal cancer.

Front Chem

August 2025

Guangzhou Key Laboratory of Formula-Pattern Research Center, School of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Jinan University, Guangzhou, China.

Introduction: Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. The FOLFOX regimen (oxaliplatin + calcium folinate + 5-fluorouracil) serves as the primary treatment for advanced CRC clinically, yet its application is significantly limited by substantial toxic side effects. Erianin, a natural compound from Chinese medicine Lindl, demonstrates significant potential in both tumor growth inhibition and chemotherapy toxicity reduction.

View Article and Find Full Text PDF

Background: Personalized medicine has transformed disease management by focusing on individual characteristics, driven by advancements in genome mapping and biomarker discoveries.

Objectives: This study aims to develop a predictive model for the early detection of treatment-related cardiac side effects in breast cancer patients by integrating clinical data, high-sensitivity Troponin-T (hs-TropT), radiomics, and dosiomics. The ultimate goal is to identify subclinical cardiotoxicity before clinical symptoms manifest, enabling personalized surveillance strategies.

View Article and Find Full Text PDF

This systematic review explores the impact of diuretic timing and strategy on outcomes in patients with acute decompensated heart failure (ADHF). A total of seven studies were included, comprising randomized controlled trials (RCTs), pre-specified sub-analyses, and observational data. Early administration of intravenous loop diuretics, particularly within the first 60 to 90 minutes of hospital arrival, was generally associated with improved short-term outcomes, including reduced in-hospital and 30-day mortality.

View Article and Find Full Text PDF

Background: Cardiac biomarkers are important components for diagnosing perioperative myocardial infarction (MI). Efforts to detect MI by biomarker-release only faced heavy criticism, because cardiac biomarker-release has also been observed in situations that are not always related to cell death (e.g.

View Article and Find Full Text PDF

Atherosclerosis is the most important etiology of acute myocardial infarction, which is considered an inflammatory disease with specific cellular and molecular responses. Recent research has linked hematological variables as biomarkers of the severity of coronary artery disease. Studies suggest that nucleated red blood cells (NRBCs), neutrophil to lymphocyte ratio (NLR), and mean platelet volume (MPV) may serve as components of a laboratory model or hematological scoring system for in-hospital surveillance.

View Article and Find Full Text PDF